Ondansetron - Transcept Pharmaceuticals

Drug Profile

Ondansetron - Transcept Pharmaceuticals

Alternative Names: Setrodon; TO-2061

Latest Information Update: 28 May 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Transcept Pharmaceuticals
  • Developer Transcept Pharmaceuticals Inc
  • Class Antiemetics; Antipsychotics; Carbazoles; Imidazoles; Pyrimidinones; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Obsessive-compulsive disorders

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 17 Jan 2013 Transcept Pharmaceuticals terminates its phase II trial in Obsessive compulsive disorders in USA and Mexico (NCT01275248)
  • 21 Dec 2012 Discontinued - Phase-II for Obsessive-compulsive disorders in Mexico (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top